SG11201402556RA - Dosage regime for apolipoprotein formulations - Google Patents

Dosage regime for apolipoprotein formulations

Info

Publication number
SG11201402556RA
SG11201402556RA SG11201402556RA SG11201402556RA SG11201402556RA SG 11201402556R A SG11201402556R A SG 11201402556RA SG 11201402556R A SG11201402556R A SG 11201402556RA SG 11201402556R A SG11201402556R A SG 11201402556RA SG 11201402556R A SG11201402556R A SG 11201402556RA
Authority
SG
Singapore
Prior art keywords
dosage regime
apolipoprotein formulations
apolipoprotein
formulations
regime
Prior art date
Application number
SG11201402556RA
Inventor
Craig Rayner
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011905368A external-priority patent/AU2011905368A0/en
Application filed by Csl Ltd filed Critical Csl Ltd
Publication of SG11201402556RA publication Critical patent/SG11201402556RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201402556RA 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations SG11201402556RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2011905368A AU2011905368A0 (en) 2011-12-21 Dosing regime for apolipoprotein formulations
PCT/AU2012/001345 WO2013090978A1 (en) 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations

Publications (1)

Publication Number Publication Date
SG11201402556RA true SG11201402556RA (en) 2014-10-30

Family

ID=48667485

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201402556RA SG11201402556RA (en) 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations

Country Status (17)

Country Link
US (3) US20140378376A1 (en)
EP (1) EP2793913B1 (en)
JP (2) JP6144276B2 (en)
KR (3) KR20140107536A (en)
CN (2) CN113398245A (en)
AU (1) AU2012310259C1 (en)
BR (1) BR112014014403A2 (en)
CA (1) CA2857968A1 (en)
DK (1) DK2793913T3 (en)
ES (1) ES2955110T3 (en)
HK (1) HK1199813A1 (en)
IL (1) IL233236A0 (en)
MX (1) MX2014006589A (en)
PL (1) PL2793913T3 (en)
RU (1) RU2014129505A (en)
SG (1) SG11201402556RA (en)
WO (1) WO2013090978A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9645037B2 (en) 2011-09-28 2017-05-09 Hunter Engineering Company Method and apparatus for wheel assembly lateral force measurement
KR20140107536A (en) * 2011-12-21 2014-09-04 시에스엘 리미티드 Dosage regime for apolipoprotein formulations
KR20240044543A (en) 2016-11-10 2024-04-04 시에스엘 리미티드 Reconstituted high density lipoprotein treatment of myocardial infarction

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61152632A (en) * 1984-12-26 1986-07-11 Dai Ichi Seiyaku Co Ltd Antiarteriosclerotic agent
US5652339A (en) 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
EP2343317A1 (en) * 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
IL161110A0 (en) * 2001-09-28 2004-08-31 Esperion Therapeutics Inc Prevention and treatment of restenosis by local admistration of drug
JP2006507223A (en) * 2002-05-17 2006-03-02 エスペリオン セラピューティクス，インコーポレイテッド Method for treating disorders of dyslipidemia
AU2003254202A1 (en) * 2002-07-30 2004-02-16 Esperion Therapeutics, Inc. Methods of using non-human animal apoliprotein a-i protein
PE20050438A1 (en) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc PHARMACEUTICAL FORMULAS, METHODS AND DOSING REGIMES FOR THE TREATMENT AND PREVENTION OF ACUTE CORONARY SYNDROMES
AP2006003578A0 (en) * 2003-10-20 2006-04-30 Esperion Therapeutics Inc Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes.
CA2619943A1 (en) * 2005-08-26 2007-03-01 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
US20090297577A1 (en) * 2008-06-02 2009-12-03 Medtronic Vascular, Inc. Local Delivery of Apolipoproteins and Their Derivatives
KR20140107536A (en) * 2011-12-21 2014-09-04 시에스엘 리미티드 Dosage regime for apolipoprotein formulations

Also Published As

Publication number Publication date
EP2793913B1 (en) 2023-06-21
BR112014014403A2 (en) 2017-06-13
ES2955110T3 (en) 2023-11-28
WO2013090978A1 (en) 2013-06-27
JP2017128586A (en) 2017-07-27
DK2793913T3 (en) 2023-08-21
CN113398245A (en) 2021-09-17
US20240216467A1 (en) 2024-07-04
AU2012310259B2 (en) 2015-07-30
NZ624558A (en) 2015-08-28
EP2793913A1 (en) 2014-10-29
HK1199813A1 (en) 2015-07-24
JP6144276B2 (en) 2017-06-07
AU2012310259A1 (en) 2013-07-11
RU2017129700A (en) 2019-02-04
KR20190084334A (en) 2019-07-16
AU2012310259C1 (en) 2016-07-14
RU2017129700A3 (en) 2021-02-26
EP2793913A4 (en) 2015-06-10
MX2014006589A (en) 2014-10-17
PL2793913T3 (en) 2023-11-06
CA2857968A1 (en) 2013-06-27
JP2015500840A (en) 2015-01-08
US20140378376A1 (en) 2014-12-25
IL233236A0 (en) 2014-08-31
RU2014129505A (en) 2016-02-10
US20160175392A1 (en) 2016-06-23
KR20140107536A (en) 2014-09-04
CN104010646A (en) 2014-08-27
KR20200037879A (en) 2020-04-09

Similar Documents

Publication Publication Date Title
HRP20181896T1 (en) Pharmaceutical formulations
GB201113662D0 (en) Pharmaceutical compositions
ZA201308208B (en) Pharmaceutical compositions
PL2776416T3 (en) Pharmaceutical compounds
HK1199824A1 (en) Pharmaceutical compositions
RS61643B1 (en) Administration regime for nitrocatechols
HK1201534A1 (en) Pharmaceutical compounds
GB201119799D0 (en) Pharmaceutical compounds
GB201118876D0 (en) Pharmaceutical compounds
GB201113163D0 (en) Pharmaceutical compounds
GB201118181D0 (en) Pharmaceutical compositions
HK1199813A1 (en) Dosage regime for apolipoprotein formulations
EP2714715A4 (en) Pharmaceutical compositions
AU2011905368A0 (en) Dosing regime for apolipoprotein formulations
GB201111577D0 (en) Pharmaceutical formulations
GB201113730D0 (en) Solid dosage form
GB201118874D0 (en) Pharmaceutical compounds
GB201118875D0 (en) Pharmaceutical compounds
GB201117359D0 (en) Pharmaceutical compounds
GB201105026D0 (en) Pharmaceutical compounds